Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor Blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT06333860 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06333860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06333860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor Blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Lead sponsor
AbbVie
Phase
Phase 4
Overall status
Completed
Start date
May 10, 2024
Completion date
March 19, 2026
Enrollment
393 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

moderate plaque psoriasis